U.S. Markets close in 1 hr 23 mins
  • S&P 500

    4,684.36
    +92.69 (+2.02%)
     
  • Dow 30

    35,724.72
    +497.69 (+1.41%)
     
  • Nasdaq

    15,675.62
    +450.47 (+2.96%)
     
  • Russell 2000

    2,269.56
    +66.08 (+3.00%)
     
  • Crude Oil

    72.22
    +2.73 (+3.93%)
     
  • Gold

    1,785.60
    +6.10 (+0.34%)
     
  • Silver

    22.56
    +0.30 (+1.33%)
     
  • EUR/USD

    1.1261
    -0.0025 (-0.2252%)
     
  • 10-Yr Bond

    1.4700
    +0.0360 (+2.51%)
     
  • Vix

    21.88
    -5.30 (-19.50%)
     
  • GBP/USD

    1.3237
    -0.0023 (-0.1761%)
     
  • USD/JPY

    113.5900
    +0.1000 (+0.0881%)
     
  • BTC-USD

    51,144.34
    +1,921.09 (+3.90%)
     
  • CMC Crypto 200

    1,317.01
    -4.27 (-0.32%)
     
  • FTSE 100

    7,339.90
    +107.62 (+1.49%)
     
  • Nikkei 225

    28,455.60
    +528.23 (+1.89%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ACAD, EBS and FREQ

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / June 18, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)
Class Period: June 15, 2020 - April 4, 2021
Lead Plaintiff Deadline: June 21, 2021

The ACAD lawsuit alleges that throughout the class period, Acadia Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the materials submitted in support of the pimavanserin supplemental new drug application (sDNA) contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the Food and Drug Administration Agency was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ACAD: http://www.kleinstocklaw.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?id=17019&from=1

Emergent Biosolutions Inc. (NYSE:EBS)
Class Period: April 24, 2020 - April 16, 2021
Lead Plaintiff Deadline: June 21, 2021

The complaint alleges that throughout the class period Emergent Biosolutions Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Emergent's Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (ii) these longstanding contamination risks and quality control issues at Emergent's facility led to a string of FDA citations; (iii) the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (iv) as a result of the foregoing, Defendants' public statements about Emergent's ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and/or misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in EBS: http://www.kleinstocklaw.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?id=17019&from=1

Frequency Therapeutics, Inc. (NASDAQ:FREQ)
Class Period: November 16, 2020 - March 22, 2021
Lead Plaintiff Deadline: August 2, 2021

The complaint alleges that during the class period Frequency Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.

Learn about your recoverable losses in FREQ: https://www.kleinstocklaw.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?id=17019&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/652387/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-ACAD-EBS-and-FREQ